Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Bellet

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Hypertension (Dallas, Tex. : 1979)|February 18, 2020
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in HypertensionPierre Verweij, Parisa Danaietash, Bruno Flamion, et al.
Journal of the American Society of Hypertension : JASH|August 14, 2010
Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertensionCharlotte Jones-Burton, Joseph Rubino, Sophie Roy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 10, 2022
Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentanParisa Danaietash, Pierre Verweij, Ji-Guang Wang, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Hypertension (Dallas, Tex. : 1979)|February 18, 2020
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in HypertensionPierre Verweij, Parisa Danaietash, Bruno Flamion, et al.
Journal of the American Society of Hypertension : JASH|August 14, 2010
Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertensionCharlotte Jones-Burton, Joseph Rubino, Sophie Roy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 10, 2022
Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentanParisa Danaietash, Pierre Verweij, Ji-Guang Wang, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
Pageof 1